Previous studies have shown that proteasome inhibitors have better antitumor efficacy in patients with ABC-DLBCL than in patients with GCB-DLBCL, probably due to higher p65 expression in the ABC subtype [45, 48, 52]. Here, RELA is linked to diffuse large B-cell lymphoma.